DK3439665T3 - Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister - Google Patents
Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister Download PDFInfo
- Publication number
- DK3439665T3 DK3439665T3 DK17767701.0T DK17767701T DK3439665T3 DK 3439665 T3 DK3439665 T3 DK 3439665T3 DK 17767701 T DK17767701 T DK 17767701T DK 3439665 T3 DK3439665 T3 DK 3439665T3
- Authority
- DK
- Denmark
- Prior art keywords
- neurodegenerate
- alpha5
- cognitive
- treatment
- receptor agonists
- Prior art date
Links
- 102000027484 GABAA receptors Human genes 0.000 title 1
- 108091008681 GABAA receptors Proteins 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310409P | 2016-03-18 | 2016-03-18 | |
| PCT/US2017/023206 WO2017161370A1 (en) | 2016-03-18 | 2017-03-20 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3439665T3 true DK3439665T3 (da) | 2022-09-26 |
Family
ID=59851645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17767701.0T DK3439665T3 (da) | 2016-03-18 | 2017-03-20 | Behandling af kognitive og sindsstemningssymptomer ved neurodegenerative og neuropsykiatriske lidelser med alpha5-holdige gabaa-receptoragonister |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10906909B2 (enExample) |
| EP (2) | EP4129297A1 (enExample) |
| JP (2) | JP7023876B2 (enExample) |
| AU (2) | AU2017235665B2 (enExample) |
| CA (1) | CA3016491A1 (enExample) |
| CY (1) | CY1125576T1 (enExample) |
| DK (1) | DK3439665T3 (enExample) |
| ES (1) | ES2926918T3 (enExample) |
| HR (1) | HRP20221098T1 (enExample) |
| HU (1) | HUE059774T2 (enExample) |
| LT (1) | LT3439665T (enExample) |
| PL (1) | PL3439665T3 (enExample) |
| PT (1) | PT3439665T (enExample) |
| RS (1) | RS63674B1 (enExample) |
| SI (1) | SI3439665T1 (enExample) |
| SM (1) | SMT202200372T1 (enExample) |
| WO (1) | WO2017161370A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017313753B2 (en) | 2016-08-16 | 2022-01-27 | The Trustees Of Columbia University In The City Of New York | GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma |
| US12636291B2 (en) * | 2019-02-13 | 2026-05-26 | Centre For Addiction And Mental Health | Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors |
| WO2020191047A1 (en) * | 2019-03-18 | 2020-09-24 | Neurocycle Therapeutics, Inc. | Use of gabaa receptor modulators for treatment of pain |
| US12649738B2 (en) | 2020-03-26 | 2026-06-09 | Richter Gedeon Nyrt. | 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| JP2024533306A (ja) * | 2021-09-08 | 2024-09-12 | ユーダブリューエム・リサーチ・ファウンデーション，インコーポレーテッド | 認知および気分症状の処置のためのイミダゾベンゾジアゼピン |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| WO2023059443A1 (en) * | 2021-10-07 | 2023-04-13 | Pantherics Incorporated | Methods and compounds for treating inflammation |
| US20260125388A1 (en) * | 2022-10-04 | 2026-05-07 | Uwm Research Foundation, Inc. | Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation |
| IT202400001089A1 (it) * | 2024-01-22 | 2025-07-22 | Fondazione St Italiano Tecnologia | Composti e composizioni per l'uso nel ripristino di deficit cognitivi e comportamentali e nel miglioramento della memoria di individui nati pretermine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA755418B (en) | 1974-09-11 | 1977-06-29 | Hoffmann La Roche | Diazepine derivatives |
| US4226768A (en) | 1979-05-29 | 1980-10-07 | Hoffmann-La Roche Inc. | Process for the preparation of imidazobenzodiazepines |
| US20030176456A1 (en) | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| USRE47475E1 (en) | 2002-03-28 | 2019-07-02 | Wisys Technology Foundation, Inc. | Selective agents for pain suppression |
| WO2003082832A2 (en) | 2002-03-28 | 2003-10-09 | Wisys Technology Foundation, Inc. | Anxiolytic agents with reduced sedative and ataxic effects |
| US8835424B2 (en) | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
| AU2005260650A1 (en) | 2004-06-30 | 2006-01-12 | Wisys Technology Foundation, Inc. | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects |
| US7595395B2 (en) * | 2005-05-16 | 2009-09-29 | Wisys Technology Foundation | Gabaergic agents to treat memory deficits |
| US20100130479A1 (en) | 2005-05-16 | 2010-05-27 | Cook James M | Gabaergic Agents to Treat Memory Deficits |
| US7858649B2 (en) | 2005-10-14 | 2010-12-28 | Neurosearch A/S | Imidazole derivatives and their use for modulating the GABAA receptor complex |
| DE102006023554A1 (de) | 2006-05-19 | 2007-11-22 | Zf Friedrichshafen Ag | Ermittlung der Drehzahl einer Getriebewelle |
| US8119629B2 (en) | 2007-10-03 | 2012-02-21 | Bristol-Meyers Squibb Company | Carboxamide GABAA α2 modulators |
| US8923318B2 (en) | 2008-10-02 | 2014-12-30 | Telefonaktiebolaget L M Ericsson (Publ) | Wireless communication system and method for assigning a channel in said wireless communication system |
| US20100261711A1 (en) | 2009-03-20 | 2010-10-14 | Wisys Technology Foundation | Selective anticonvulsant agents and their uses |
| US9006233B2 (en) | 2011-04-28 | 2015-04-14 | Uwm Research Foundation, Inc. | Gabaergic receptor subtype selective ligands and their uses |
| CA2885148A1 (en) | 2012-09-21 | 2014-03-27 | Uwm Research Foundation, Inc. | Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma |
| WO2016154031A1 (en) | 2015-03-20 | 2016-09-29 | Uwm Research Foundation, Inc. | Gabaergic ligands and their uses |
-
2017
- 2017-03-20 EP EP22181243.1A patent/EP4129297A1/en active Pending
- 2017-03-20 DK DK17767701.0T patent/DK3439665T3/da active
- 2017-03-20 SM SM20220372T patent/SMT202200372T1/it unknown
- 2017-03-20 WO PCT/US2017/023206 patent/WO2017161370A1/en not_active Ceased
- 2017-03-20 ES ES17767701T patent/ES2926918T3/es active Active
- 2017-03-20 HU HUE17767701A patent/HUE059774T2/hu unknown
- 2017-03-20 PL PL17767701.0T patent/PL3439665T3/pl unknown
- 2017-03-20 LT LTEPPCT/US2017/023206T patent/LT3439665T/lt unknown
- 2017-03-20 EP EP17767701.0A patent/EP3439665B1/en active Active
- 2017-03-20 RS RS20220892A patent/RS63674B1/sr unknown
- 2017-03-20 PT PT177677010T patent/PT3439665T/pt unknown
- 2017-03-20 AU AU2017235665A patent/AU2017235665B2/en active Active
- 2017-03-20 JP JP2018568186A patent/JP7023876B2/ja active Active
- 2017-03-20 SI SI201731230T patent/SI3439665T1/sl unknown
- 2017-03-20 CA CA3016491A patent/CA3016491A1/en active Pending
- 2017-03-20 US US16/086,053 patent/US10906909B2/en active Active
- 2017-03-20 HR HRP20221098TT patent/HRP20221098T1/hr unknown
-
2020
- 2020-12-15 US US17/122,745 patent/US11753412B2/en active Active
-
2022
- 2022-02-08 JP JP2022017827A patent/JP7515526B2/ja active Active
- 2022-09-27 CY CY20221100636T patent/CY1125576T1/el unknown
- 2022-11-23 AU AU2022275446A patent/AU2022275446B2/en active Active
-
2023
- 2023-08-02 US US18/363,933 patent/US12180216B2/en active Active
-
2024
- 2024-11-12 US US18/944,947 patent/US20250179080A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017235665A1 (en) | 2018-09-27 |
| HUE059774T2 (hu) | 2023-01-28 |
| US20250179080A1 (en) | 2025-06-05 |
| EP3439665A4 (en) | 2019-11-27 |
| EP3439665A1 (en) | 2019-02-13 |
| CA3016491A1 (en) | 2017-09-21 |
| JP2019509340A (ja) | 2019-04-04 |
| EP4129297A1 (en) | 2023-02-08 |
| JP7023876B2 (ja) | 2022-02-22 |
| RS63674B1 (sr) | 2022-11-30 |
| PL3439665T3 (pl) | 2023-01-16 |
| US11753412B2 (en) | 2023-09-12 |
| ES2926918T3 (es) | 2022-10-31 |
| JP2022065035A (ja) | 2022-04-26 |
| US20240083905A1 (en) | 2024-03-14 |
| WO2017161370A1 (en) | 2017-09-21 |
| AU2022275446B2 (en) | 2025-01-02 |
| SI3439665T1 (sl) | 2023-05-31 |
| EP3439665B1 (en) | 2022-06-29 |
| SMT202200372T1 (it) | 2022-11-18 |
| US20210309662A1 (en) | 2021-10-07 |
| AU2017235665B2 (en) | 2022-12-08 |
| CY1125576T1 (el) | 2026-02-25 |
| LT3439665T (lt) | 2022-10-10 |
| WO2017161370A8 (en) | 2018-09-27 |
| US12180216B2 (en) | 2024-12-31 |
| AU2022275446A1 (en) | 2023-01-05 |
| US20200181146A1 (en) | 2020-06-11 |
| JP7515526B2 (ja) | 2024-07-12 |
| PT3439665T (pt) | 2022-09-27 |
| HRP20221098T1 (hr) | 2022-11-25 |
| US10906909B2 (en) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125576T1 (el) | Αγωγη γνωσιακων συμπτωματων και συμπτωματων διαθεσης σε νευροεκφυλιστικες και νευροψυχιατρικες διαταραχες με αγωνιστες αλφα5- περιεχοντων υποδοχεων gabaa | |
| IL258412A (en) | Melanocortin-4 receptor (mc4r) agonists for use in treating melanocortin-4 receptor pathway-associated disorders | |
| IL263484A (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| IL290985A (en) | Methods of diagnosing and treating anxiety disorder | |
| DK3240554T3 (da) | Blautia stercosis og wexlerae til anvendelse til behandling af inflammatoriske og autoimmune sygdomme | |
| HUE059559T2 (hu) | 5HT agonisták az epilepsziás rendellenességek kezelésére | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| PT3119397T (pt) | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| IL264098A (en) | Modified ligand-gated ion channels and methods of use | |
| DK3973959T3 (da) | Behandling af kolestatisk kløe med seladelpar | |
| DK3519049T3 (da) | Sikker og effektiv fremgangsmåde til behandling af psoriasis med specifikt anti-il23-antistof | |
| DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
| EP3328374A4 (en) | GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES | |
| DK3419622T3 (da) | Behandling af neurodegenerativ øjensygdom med pridopidin | |
| DK3512517T3 (da) | Anvendelse af pridopidin til behandling af angst og depression | |
| DK3506904T3 (da) | Behandling af demens | |
| DK3481856T3 (da) | Materialer og metoder til behandling af smerterelaterede lidelser | |
| DK3426303T3 (da) | Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner | |
| DK3484423T3 (da) | Anordning til hypertermisk behandling af kløe | |
| DK3426302T3 (da) | Behandling af autoimmunsygdomme med kombinationer af rxr-agonister og skjoldbruskkirtelhormoner | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| LT3250600T (lt) | Autoimuninių sutrikimų gydymas cd154 antikūnais | |
| DK3556383T5 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
| DK2928910T3 (da) | Behandling af inflammation, autoimmune og neurodegenerative sygdomme med immunosuppressive tat-derivat polypeptider |